Public health & disease

From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.

Abstract image with woman's face repeated, for article on psychedelics approved as medicines

Australia becomes world’s first country to officially recognize psychedelics as medicines

By / / Good News For Humankind

Psychedelic medicine just crossed a historic threshold — Australia is now the first country to give psychiatrists a legal pathway to prescribe psilocybin and MDMA as regulated treatments for PTSD and treatment-resistant depression. For patients who have cycled through every available option without relief, that’s a genuinely new door opening. The decision followed thousands of public submissions and a growing body of clinical evidence, including a landmark New Zealand Journal of Medicine study on psilocybin’s efficacy. It shows that political barriers — not just scientific ones — can eventually fall when evidence and public pressure align.\n\n—\n\n**Word count: 95**

Fungal infection under microscope, for article on pan-fungal vaccine

First vaccine to target deadly fungal infections passes preclinical tests

By / / Good News For Humankind

Fungal infections kill an estimated 1.6 million people every year, yet until now no vaccine has ever existed for any of the major culprits. Researchers at the University of Georgia have developed a single shot that trains the immune system to recognize all three deadliest fungal genera simultaneously — a feat never before demonstrated in peer-reviewed research. Crucially, it reduced illness and death in immunocompromised animals, the very people most at risk. For a disease category the WHO only recently recognized as a global emergency, this candidate offers the first real hope of prevention.\n\n*(Word count: 88)*

Vials of blood, for article on cancer diagnostics Africa

Morocco becomes first African nation to produce its own cancer diagnosis tests

By / / Good News For Humankind

Morocco’s research foundation has developed cancer diagnostic tests made entirely in Africa—a breakthrough that promises to slash waiting times from weeks or months down to hours, and potentially cut costs in half. The leukemia test, already used on 400 patients, sidesteps the costly delays of importing kits from Europe or North America. Because results no longer need to travel abroad for interpretation, patients can receive treatment sooner when it matters most. This success builds on Morocco’s earlier COVID-19 test and positions African nations to control their own medical futures rather than depend on distant supply chains.\n\n**Word count: 95**

Vials and syringes in a lab, for article on not-for-profit drug access

Pfizer to sell all its drugs in 45 low-income countries at non-profit price

By / / Good News For Humankind

Pfizer’s not-for-profit pricing pledge now spans all 500 of its medicines — including chemotherapy and oral cancer treatments — across 45 of the world’s lowest-income countries. That’s a major expansion of an accord the company launched in 2022, which originally covered only patented drugs. By including off-patent medicines too, Pfizer is acknowledging that even decades-old cancer treatments often remain out of reach where generic supply chains never took hold. For patients across much of sub-Saharan Africa and South Asia, where cancer and heart disease are rising fast, this could quietly move the floor on what’s possible. And when the world’s largest drugmaker makes a move this broad, the rest of the industry tends to notice.

Cannabis being weighed, for article on legal cannabis dispensary

New York opens its first legal recreational cannabis dispensary

By / / Good News For Humankind

New York’s first legal recreational cannabis dispensary opened with a meaningful twist: the very first retail license went to Housing Works, a nonprofit that serves people with HIV, homeless New Yorkers, and the formerly incarcerated. Revenue from the shop will flow back into those social services, turning a newly legal market into direct support for communities hit hardest by the war on drugs. New York reserved its earliest licenses for nonprofits, people with past marijuana convictions and their families, women- and minority-owned businesses, and veterans, backed by a $200 million equity fund. It’s an ambitious bet that legalization can repair harm rather than just generate profit, and other states are paying close attention.

DNA, for article on artificial DNA cancer

In a world first, Japenese scientists use artificial DNA to kill cancer cells

By / / Good News For Humankind

Artificial DNA that turns cancer’s own biology against itself marks a genuine conceptual leap in oncology. Japanese researchers at the University of Tokyo engineered synthetic molecules that lie dormant until they detect a chemical cancer cells overproduce — then restructure themselves into a signal the immune system reads as a threat, destroying the tumor from within. Early tests spanned multiple cancer types, suggesting broad potential. This kind of precision — working with the body’s existing defenses rather than overwhelming them — is exactly the direction cancer medicine has been reaching toward, and this research moves that goal meaningfully closer.

3M mask, for article on PFAS phase-out

3M to end ‘forever chemicals’ output at cost of up to $2.3 bn

By / / Good News For Humankind

3M, one of the world’s largest makers of PFAS, will halt all production of these “forever chemicals” by the end of 2025, walking away from a business that brought in roughly $1.3 billion a year. The company expects to absorb up to $2.3 billion in pre-tax charges to exit — a sign it sees long-term liability as the bigger risk than lost revenue. The move follows mounting pressure from regulators, lawsuits, and a coalition of fund managers overseeing $8 trillion in assets who urged dozens of companies to phase PFAS out. Compounds linked to cancer, thyroid disruption, and developmental harm have turned up in drinking water and food supplies worldwide, and 3M’s deadline signals that the era of treating them as ordinary industrial inputs is drawing to a close.